- Home
- CCRD vs CHRS Comparison
CCRD vs CHRS Comparison
Compare CCRD & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCRD
- CHRS
- Stock Information
- Founded
- CCRD 1973
- CHRS 2010
- Country
- CCRD United States
- CHRS United States
- Employees
- CCRD N/A
- CHRS N/A
- Industry
- CCRD
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCRD
- CHRS Health Care
- Exchange
- CCRD Nasdaq
- CHRS Nasdaq
- Market Cap
- CCRD 157.9M
- CHRS 84.2M
- IPO Year
- CCRD N/A
- CHRS 2014
- Fundamental
- Price
- CCRD $27.23
- CHRS $0.90
- Analyst Decision
- CCRD Hold
- CHRS Buy
- Analyst Count
- CCRD 1
- CHRS 3
- Target Price
- CCRD $21.00
- CHRS $4.68
- AVG Volume (30 Days)
- CCRD 99.7K
- CHRS 1.3M
- Earning Date
- CCRD 07-31-2025
- CHRS 08-07-2025
- Dividend Yield
- CCRD N/A
- CHRS N/A
- EPS Growth
- CCRD 187.14
- CHRS N/A
- EPS
- CCRD 0.86
- CHRS N/A
- Revenue
- CCRD $61,011,000.00
- CHRS $272,251,000.00
- Revenue This Year
- CCRD $17.35
- CHRS N/A
- Revenue Next Year
- CCRD N/A
- CHRS $99.43
- P/E Ratio
- CCRD $31.59
- CHRS $2.07
- Revenue Growth
- CCRD 12.31
- CHRS 19.87
- 52 Week Low
- CCRD $11.57
- CHRS $0.66
- 52 Week High
- CCRD $31.99
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- CCRD 47.22
- CHRS 59.04
- Support Level
- CCRD $28.50
- CHRS $0.73
- Resistance Level
- CCRD $31.26
- CHRS $0.82
- Average True Range (ATR)
- CCRD 1.23
- CHRS 0.04
- MACD
- CCRD -0.27
- CHRS 0.02
- Stochastic Oscillator
- CCRD 12.62
- CHRS 88.02
About CCRD CoreCard Corporation
CoreCard Corp is engaged in the business of providing technology solutions and processing services to the financial technology and services market. It designs, develops and markets a comprehensive suite of software solutions to program managers, accounts receivable businesses, financial institutions, retailers and processors to manage their credit and debit cards, prepaid cards, private label cards, fleet cards, buy now pay later programs, loyalty programs and accounts receivable and loan transactions. The CoreCard software platform and modules include CoreENGINE, CoreISSUE, CoreFRAUD, CoreCOLLECT, CoreAPP, CoreMONEY and CoreACQUIRE. Its customers are located in the U.S, European Union and the Middle East of which key revenue is derived from the U.S.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.